The Efficacy and Safety of Selexipag as an Add-On to Standard-of-Care Therapy in Patients With Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension After Surgical and/or Interventional Treatment (SELECT)

Autor: N.H. Kim, R. Channick, M. Delcroix, M. Madani, J. Pepke-Zaba, J.I. Borissoff, V. Easton, S. Gesang, D. Richard, A. Ghofrani

Publikováno v: B97. RISKY BUSINESS: TREATMENTS AND CLINICAL TARGETS IN PULMONARY HYPERTENSION.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::de0d09c1936b700069df2182044e73a9
https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4235

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P42 Pulmonary embolism (PE) to chronic thromboembolic pulmonary disease (CTEPD): Findings from a survey of UK physicians

Autor: J Pepke-Zaba, L Howard, D Kiely, T Donovan-Rodriguez, M Johnson

Publikováno v: ‘Mission (Im)possible I’ – Pulmonary vascular disease.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3a9da80fb7946240c6c6785b24d1c325
https://doi.org/10.1136/thorax-2022-btsabstracts.178

Medical bridging therapy before pulmonary endarterectomy?

Autor: D P Jenkins, J Pepke-Zaba, E Fadel, G Simonneau, N H Kim, M M Madani, H Matsubara, M Delcroix, I M Lang, E Mayer

Publikováno v: 13.01 - Pulmonary hypertension.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1039503c925441734c1e6040a253999d
https://doi.org/10.1183/13993003.congress-2022.2858

Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension

Autor: Lars Harbaum, Christopher J. Rhodes, John Wharton, Allan Lawrie, Jason H. Karnes, Ankit A. Desai, William C. Nichols, Marc Humbert, David Montani, Barbara Girerd, Olivier Sitbon, Mario Boehm, Tatyana Novoyatleva, Ralph T. Schermuly, H. Ardeschir Ghofrani, Mark Toshner, David G. Kiely, Luke S. Howard, Emilia M. Swietlik, Stefan Gräf, Maik Pietzner, Nicholas W. Morrell, Martin R. Wilkins, L Southgate, RD Machado, J Martin, WH Ouwehand, MW Pauciulo, A Arora, K Lutz, F Ahmad, SL Archer, R Argula, ED Austin, D Badesch, S Bakshi, C Barnett, R Benza, N Bhatt, CD Burger, M Chakinala, J Elwing, T Fortin, RP Frantz, A Frost, JGN Garcia, J Harley, H He, NS Hill, R Hirsch, D Ivy, J Klinger, T Lahm, K Marsolo, LJ Martin, SD Nathan, RJ Oudiz, Z Rehman, I Robbins, DM Roden, EB Rosenzweig, G Saydain, R Schilz, RW Simms, M Simon, H Tang, AY Tchourbanov, T Thenappan, F Torres, AK Walsworth, RE Walter, RJ White, J Wilt, D Yung, R Kittles, J Aman, J Knight, KB Hanscombe, H Gall, A Ulrich, HJ Bogaard, C Church, JG Coghlan, R Condliffe, PA Corris, C Danesino, CG Elliott, A Franke, S Ghio, JSR Gibbs, AC Houweling, G Kovacs, M Laudes, RV MacKenzie Ross, S Moledina, M Newnham, A Olschewski, H Olschewski, AJ Peacock, J Pepke-Zaba, L Scelsi, W Seeger, CM Shaffer, O Sitbon, J Suntharalingam, C Treacy, A Vonk Noordegraaf, Q Waisfisz, SJ Wort, RC Trembath, M Germain, I Cebola, J Ferrer, P Amouyel, S Debette, M Eyries, F Soubrier, DA Trégouët

Rationale: Pulmonary arterial hypertension (PAH) is characterized by structural remodeling of pulmonary arteries and arterioles. Underlying biological processes are likely reflected in a perturbation of circulating proteins. Objectives: To quantify a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f363dc083e705c01eb9c6d70a4b67afd
https://www.repository.cam.ac.uk/handle/1810/340465